RB1 and breast carcinoma: In the phase II trial (UPCC03909; NCT01037790), endocrine-resistant, HR + and Rb + advanced breast cancer patients responded favorably to single-agent palbociclib (125 mg/day, 1–21 days of a 28-day cycle) [73].